Search

Your search keyword '"Milloy, MJ"' showing total 419 results

Search Constraints

Start Over You searched for: Author "Milloy, MJ" Remove constraint Author: "Milloy, MJ"
419 results on '"Milloy, MJ"'

Search Results

301. Factors associated with illicit methadone injecting in a Canadian setting.

302. Gender differences in access to methadone maintenance therapy in a Canadian setting.

303. Pain Among High-Risk Patients on Methadone Maintenance Treatment.

304. Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids.

306. Impact of incarceration on rates of methadone use in a community recruited cohort of injection drug users.

307. Socioeconomic marginalisation in the structural production of vulnerability to violence among people who use illicit drugs.

308. Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada.

309. Factors associated with willingness to participate in a pharmacologic addiction treatment clinical trial among people who use drugs.

310. The causal effect of opioid substitution treatment on HAART medication refill adherence.

311. Factors associated with willingness to take extended release naltrexone among injection drug users.

312. Negotiating structural vulnerability following regulatory changes to a provincial methadone program in Vancouver, Canada: A qualitative study.

313. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis.

314. Associations between childhood trauma and non-fatal overdose among people who inject drugs.

315. High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs.

316. Impact of unstable housing on all-cause mortality among persons who inject drugs.

317. High-intensity cannabis use and adherence to antiretroviral therapy among people who use illicit drugs in a Canadian setting.

318. Ongoing impact of HIV infection on mortality among people who inject drugs despite free antiretroviral therapy.

319. Factors linked to transitions in adherence to antiretroviral therapy among HIV-infected illicit drug users in a Canadian setting.

320. Predictors of liver-related death among people who inject drugs in Vancouver, Canada: a 15-year prospective cohort study.

321. The impact of drug use patterns on mortality among polysubstance users in a Canadian setting: a prospective cohort study.

322. Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada.

323. Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention.

324. Early immune adaptation in HIV-1 revealed by population-level approaches.

325. Suboptimal plasma HIV-1 RNA suppression and adherence among sex workers who use illicit drugs in a Canadian setting: an observational cohort study.

326. Timing of income assistance payment and overdose patterns at a Canadian supervised injection facility.

327. Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012.

328. Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic.

329. Relationship between hunger, adherence to antiretroviral therapy and plasma HIV RNA suppression among HIV-positive illicit drug users in a Canadian setting.

330. Methadone maintenance therapy decreases the rate of antiretroviral therapy discontinuation among HIV-positive illicit drug users.

331. Employment predicts decreased mortality among HIV-seropositive illicit drug users in a setting of universal HIV care.

332. Incarceration is associated with used syringe lending among active injection drug users with detectable plasma HIV-1 RNA: a longitudinal analysis.

333. A method for killer-cell immunoglobulin-like receptor (KIR) 3DL1/3DS1 genotyping using DNA recovered from frozen plasma.

334. Demographics, Health-Care Utilization, and Substance Use Profiles of Older Adults in Canada's Lowest Income Neighbourhood.

335. Injection drug use and HIV antiretroviral therapy discontinuation in a Canadian setting.

336. Housing status and the health of people living with HIV/AIDS.

337. High-risk drug-use practices among a large sample of Australian prisoners.

338. Improved adherence to modern antiretroviral therapy among HIV-infected injecting drug users.

339. HLA class I sequence-based typing using DNA recovered from frozen plasma.

340. Emergency department utilization among a cohort of HIV-positive injecting drug users in a Canadian setting.

341. Barriers to HIV treatment among people who use injection drugs: implications for 'treatment as prevention'.

342. Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users.

343. Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review.

344. Incidence and risk factors for non-fatal overdose among a cohort of recently incarcerated illicit drug users.

345. Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users.

346. Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy.

347. HIV treatment as prevention among injection drug users.

348. Temporal and geographic shifts in urban and nonurban cocaine-related fatal overdoses in British Columbia, Canada.

349. Ending Canada's HIV trials.

350. Physician experience and rates of plasma HIV-1 RNA suppression among illicit drug users: an observational study.

Catalog

Books, media, physical & digital resources